AERODRUG and DTF develops the NL20®, a new nebulizer for all upper airways indications, such as laryngitis or tracheitis.

• adapted particle size: MMAD=10µm
• good targetting of upper airways
• pulmonary drug deposition strongly reduce
   
  In vitro evaluation
  The NL20® nebulizer produce an aerosol with a MMAD equal to 10.1µm and with 77% of particles > 5µm.
  - More details about NL20® aerosol characteristics.
  
   
  In vivo aerosol deposition
• Two nebulizer were tested in three animal models :
  • a standard jet nebulizer ® (MMAD=4µm) usually used at hospital
  • the NL20® nebulizer (MMAD=10,1µm)
• Animal model inhaled DTPA-Tc99m aerosol with face mask
• Images scintigraphic were registered (Gamma camera E-cam, Siemens) and aerosol deposition quantified into upper and lower airways.
   

% deposition of loaded dose	Jet-nebulizer - 4µm	Prototype NL20® - 10µm
ENT	2.7 +/- 1.0	3.2 +/-2.1
Trachea	0.5 +/-0.1	1.2 +/-0.9
Stomach	2.0 +/-0.9	0.5 +/-0.7
Lungs	2.4 +/-0.4	0.4 +/-0.2
Lung/extrapulmonary	0.5 +/-0.2	0.1 +/-0.1

 

 

• The NL20® nebulizer guarantee a high drug deposition into upper airway reducing for a 6 fold the pulmonary deposition of drugs with ENT indications.
   
• In summary, the NL20® nebulizer is adapt for a topical treatment of upper airways (trachea, larynx, throat ...).
  
  NL20_PDFplaquette (in french)

Scientific communication

 Dévelopement et évaluation d’un nouveau nébuliseur ciblant les voies aériennes supérieures. Le Guellec S., Robert G., Vullo F., Gatier S., Chantrel G., Vecellio L. French ENT society congress (SFORL), 2009. Poster PDF file